Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple Myeloma

Area of Science:

• Oncology
• Epigenetics
• Hematology

Background:

• Multiple myeloma (MM) is a plasma cell malignancy that is treatable but incurable.
• Carcinogenesis and multi-therapy resistance in MM are complex processes.
• Existing understanding of MM progression and resistance mechanisms is incomplete.

Purpose of the Study:

• To investigate the role of epigenetic dysregulation in multiple myeloma carcinogenesis and therapy resistance.
• To establish a new paradigm for understanding MM progression and treatment failure.
• To identify novel therapeutic targets for multiple myeloma.

Main Methods:

• Comprehensive molecular and clinical characterization of a cohort of nearly 1,000 patients.
• Analysis spanning premalignant to late-stage refractory multiple myeloma.
• Integration of genomic, cytogenetic, and epigenetic data.

Main Results:

• Epigenetic dysregulation is a key driver of carcinogenesis and multi-therapy resistance in MM.
• Genomic and cytogenetic events facilitate epigenetic plasticity, enabling MM cells to evade constraints.
• Findings explain inter-patient genomic heterogeneity and therapy resistance emergence without new genomic alterations.

Conclusions:

• A new paradigm posits epigenetic plasticity as central to MM progression and evasion.
• Targeting epigenetic plasticity-mediated plasma cell evasion is a promising therapeutic strategy for MM.
• This framework unifies understanding of MM's complex biology and resistance mechanisms.